查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
潰瘍性大腸炎的全球市場 - 規模、佔有率、產業趨勢分析:各分子類型，各疾病類型，各給藥途徑，各地區的展望與預測(2022年～2028年)
市場調查報告書
商品編碼
1092368

潰瘍性大腸炎的全球市場 - 規模、佔有率、產業趨勢分析:各分子類型，各疾病類型，各給藥途徑，各地區的展望與預測(2022年～2028年)

Global Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 188 Pages | 訂單完成後即時交付

價格

至2028年達到90億美元，在預測期間內預計以5.7％的年複合成長率成長。市場主要由於發炎性腸道疾病的流行，潰瘍性大腸炎的病例數增加，多數主要企業對潰瘍性大腸炎專門醫藥品的開發，牽引全球潰瘍性大腸炎的市場規模。

本報告提供全球潰瘍性大腸炎市場相關調查分析，市場產業趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 市場範圍與調查手法

第2章 市場概要

  • 簡介
  • 影響市場的要素

第3章 被潰瘍性大腸炎市場展開的策略

第4章 全球潰瘍性大腸炎市場:各分子類型

  • 全球低分子市場:各地區
  • 全球生技藥品市場:各地區

第5章 全球潰瘍性大腸炎市場:各疾病類型

  • 全球輕度市場:各地區
  • 全球中度市場:各地區
  • 全球重度市場:各地區

第6章 全球潰瘍性大腸炎市場:各給藥途徑

  • 全球口服市場:各地區
  • 全球注射劑市場:各地區

第7章 全球潰瘍性大腸炎市場:各地區

  • 北美的潰瘍性大腸炎市場
  • 歐洲的潰瘍性大腸炎市場
  • 亞太地區的潰瘍性大腸炎市場
  • 南美、中東、非洲的潰瘍性大腸炎市場

第8章 企業簡介

  • Abbott Laboratories
  • Ajinomoto Co., Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi S.A.
  • InDex Pharmaceuticals Holding AB
  • Eli Lilly And Company

The Global Ulcerative Colitis Market size is expected to reach $9 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.

The global ulcerative colitis market is primarily driven by an increase in the incidence of inflammatory gastrointestinal illnesses, an increase in ulcerative colitis cases, and the development of ulcerative colitis-specific medications by a large number of important companies. As per the survey conducted by Marc D Basson on Ulcerative Colitis in 2019, ulcerative colitis affects one million persons in the United States. The high prevalence of ulcerative colitis is the driving force behind the development of ulcerative colitis medications. As the prevalence of inflammatory bowel illness rises, demand for ulcerative colitis rises, which is expected to fuel the growth of the ulcerative colitis market.

The most common kind of inflammatory bowel illness, ulcerative colitis (UC), affects a large number of people. It is widespread in most of Europe and North America, but rare in most developing Asian countries. Males are more likely to develop UC, which has a north-to-south variance. One possible cause is disparities in ultraviolet light exposure, which results in relative vitamin D insufficiency in countries near the Arctic. People who reside in lower latitudes are more prone than those who live in higher latitudes to develop UC. According to a study published in the National Center for Biotechnology Information (NCBI) in June 2020, the global incidence of ulcerative colitis is 9 to 20 cases per 100,000 people per year. The annual prevalence ranges from 156 to 291 cases per 100,000 people. Adults are more likely to develop ulcerative colitis. Nonsmokers and individuals who have just quit smoking are more likely to develop ulcerative colitis.

If ulcerative colitis is left untreated for more than 8 years, it can progress to colon cancer. Over-the-counter medications like Imodium treatment can help those with moderate symptoms of this condition. Transcription drugs such as steroid pharmaceuticals and aminosalicylates, on the other hand, are commonly used to treat the illness. In extreme situations, surgery to remove the colon may be required, which also helps to prevent colon cancer. Ulcerative colitis is also treated with several genetically modified medicines. These medications are composed of living organisms that assist to reduce inflammation by targeting inflammatory proteins like cytokines. Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab are among the genetically modified medications authorized by the US FDA for treating the illness (Entyvio).

COVID-19 Impact

COVID-19 has acted as a threat multiplier in all areas of life. The medical and psychosocial effects of the COVID-19 pandemic and pre-existing medical conditions like acute severe ulcerative colitis are multidirectional and include the effects of COVID-19 and acute severe ulcerative colitis on each other, as well as their effects on patients, their families, the healthcare system, and health-care providers. According to a study published in the Gastroenterology and Hepatology Journal in February 2021, the risk of COVID-19-related side events is greater in patients with ulcerative colitis. It remains a hazard to people with acute severe ulcerative colitis, posing an ever-increasing threat to the worldwide healthcare system. According to a paper published in June 2020 in the Inflammatory Intestinal Diseases Journal, managing inflammatory bowel disease (IBD) patients (Ulcerative Colitis and Crohn's disease) during the COVID-19 pandemic has been difficult.

Market Growth Factors

Rising incidences of Ulcerative proctitis

Ulcerative proctitis is one of the kinds of ulcerative colitis that is becoming more common. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative colitis. According to a study published in the United European Gastroenterology Journal in March 2021, the COVID-19 incidence rate per 1,000 patients with inflammatory bowel disease (ulcerative colitis) and the general population was 4.02 and 6.59, respectively. Hospitalization and intensive care unit care were required by 27.29 percent and 5.33 percent of COVID-19-positive inflammatory bowel disease patients, respectively.

The rise in ulcerative colitis patients and commercialization and an infusion of healthcare capital

The availability of sophisticated ulcerative colitis medications as a result of technological breakthroughs, as well as the growing patient pool in need of treatment, are two main catalytic drivers for the market. In addition, increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are the major trends in the Ulcerative Colitis Market. Due to increased demand for ulcerative colitis, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.

Market Restraining Factors

Concerns about patent expiry and concerns about negative side effects

The expiration of drug patents is posing a constant threat to the industry players and their revenue. There are few trustworthy medications on the market for ulcerative colitis. Failures, on the other hand, occur when patents are not renewed. The pharmaceutical industry generates the most income of any industry. UC medicines have a high level of investment and production. Patent expiration, on the other hand, can have an impact on all of these processes; capital waste is a big factor that can affect revenue rates. The ulcerative colitis market has had a lot of patent failures in recent years. It is resulting in catastrophic losses.

Molecule Type

Based on Molecule Type, the market is segmented into Small Molecules and Biologics. In 2021, the Small Molecules segment obtained the maximum revenue share of the Ulcerative Colitis Market. This is due to the large number of important players offering medications for ulcerative colitis treatment and advancement in R&D operations. Moreover, many players are putting heavy investments in creating effective medications, thereby boosting the growth of the segment.

Disease Type

Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. The Moderate UC segment held a significant revenue share of the Ulcerative Colitis Market in 2021. Urgent bowel motions, frequent bowel movements, abdominal pain, and cramps are just a few of the painful and sometimes debilitating symptoms of moderate ulcerative colitis. Managing the symptoms with medication and effective home remedies can enhance the quality of life and help a person avoid flare-ups in the future.

Route of Administration

Based on Route of Administration, the market is segmented into Oral and Injectables. In 2021, the Oral segment garnered the biggest revenue share of the Ulcerative Colitis Market. This is due to increased R&D activities in the pharmaceutical & medical device industry, growing demand for drugs required for treatment, and a surge in adoption of various types of ulcerative colitis drugs. Moreover, many people prefer to take medications through oral mode rather than injections, hence boosting the growth of the segment during the forecasting period.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America emerged as the leading region in the overall Ulcerative Colitis Market by collecting the maximum revenue share. The high growth of the segment is because of the rise in the number of ulcerative colitis patients, the presence of important companies, the expansion of the healthcare sector, and the presence of new medications in the region. Because of the presence of important companies and the rising prevalence of Ulcerative Colitis in the region, as well as continued financing for the development of new therapies for the treatment of the ailment, North America is likely to lead the ulcerative colitis market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.

Strategies deployed in Ulcerative Colitis Market

Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Mar-2021: InDex Pharmaceuticals signed an agreement with Parexel Biotech, a trusted global clinical research organization. Through this agreement, the companies would assess the effectiveness and security of the drug consumer cobitolimod for the therapy of average to critical left-sided ulcerative colitis.

Feb-2021: Merck signed an agreement to acquire Pandion, a clinical-stage biotechnology enterprise designing novel therapeutics. Through this acquisition, Merck, via a subsidiary, would commence a tender provide to acquire all remaining shares of Pandion. Additionally, this acquisition aimed to definite conditions, such as the tender shares representing at least a greatest number of Pandion's shares of completely-diluted common stock, the termination of the waiting period under the Hart-Scott-Rodino Antitrust enhancement Act, and other conventional situations.

Mar-2018: Pfizer received a Food and Drug Administration approval for XELJANZ, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S with average to serious active ulcerative colitis. Through this approval, XELJANZ would offer adults living with average to serious active ulcerative colitis now have an oral choice that assists accomplish and preserve steroid-free remission.

Scope of the Study

Market Segments covered in the Report:

By Molecule Type

  • Small Molecules
  • Biologics

By Disease Type

  • Mild
  • Moderate
  • Severe

By Route of Administration

  • Oral
  • Injectables

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Ajinomoto Co., Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi S.A.
  • InDex Pharmaceuticals Holding AB
  • Eli Lilly And Company

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Ulcerative Colitis Market, by Molecule Type
    • 1.4.2 Global Ulcerative Colitis Market, by Disease Type
    • 1.4.3 Global Ulcerative Colitis Market, by Route of Administration
    • 1.4.4 Global Ulcerative Colitis Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies deployed in Ulcerative Colitis Market

Chapter 4. Global Ulcerative Colitis Market by Molecule Type

  • 4.1 Global Small Molecules Market by Region
  • 4.2 Global Biologics Market by Region

Chapter 5. Global Ulcerative Colitis Market by Disease Type

  • 5.1 Global Mild Market by Region
  • 5.2 Global Moderate Market by Region
  • 5.3 Global Severe Market by Region

Chapter 6. Global Ulcerative Colitis Market by Route of Administration

  • 6.1 Global Oral Market by Region
  • 6.2 Global Injectables Market by Region

Chapter 7. Global Ulcerative Colitis Market by Region

  • 7.1 North America Ulcerative Colitis Market
    • 7.1.1 North America Ulcerative Colitis Market by Molecule Type
      • 7.1.1.1 North America Small Molecules Market by Country
      • 7.1.1.2 North America Biologics Market by Country
    • 7.1.2 North America Ulcerative Colitis Market by Disease Type
      • 7.1.2.1 North America Mild Market by Country
      • 7.1.2.2 North America Moderate Market by Country
      • 7.1.2.3 North America Severe Market by Country
    • 7.1.3 North America Ulcerative Colitis Market by Route of Administration
      • 7.1.3.1 North America Oral Market by Country
      • 7.1.3.2 North America Injectables Market by Country
    • 7.1.4 North America Ulcerative Colitis Market by Country
      • 7.1.4.1 US Ulcerative Colitis Market
        • 7.1.4.1.1 US Ulcerative Colitis Market by Molecule Type
        • 7.1.4.1.2 US Ulcerative Colitis Market by Disease Type
        • 7.1.4.1.3 US Ulcerative Colitis Market by Route of Administration
      • 7.1.4.2 Canada Ulcerative Colitis Market
        • 7.1.4.2.1 Canada Ulcerative Colitis Market by Molecule Type
        • 7.1.4.2.2 Canada Ulcerative Colitis Market by Disease Type
        • 7.1.4.2.3 Canada Ulcerative Colitis Market by Route of Administration
      • 7.1.4.3 Mexico Ulcerative Colitis Market
        • 7.1.4.3.1 Mexico Ulcerative Colitis Market by Molecule Type
        • 7.1.4.3.2 Mexico Ulcerative Colitis Market by Disease Type
        • 7.1.4.3.3 Mexico Ulcerative Colitis Market by Route of Administration
      • 7.1.4.4 Rest of North America Ulcerative Colitis Market
        • 7.1.4.4.1 Rest of North America Ulcerative Colitis Market by Molecule Type
        • 7.1.4.4.2 Rest of North America Ulcerative Colitis Market by Disease Type
        • 7.1.4.4.3 Rest of North America Ulcerative Colitis Market by Route of Administration
  • 7.2 Europe Ulcerative Colitis Market
    • 7.2.1 Europe Ulcerative Colitis Market by Molecule Type
      • 7.2.1.1 Europe Small Molecules Market by Country
      • 7.2.1.2 Europe Biologics Market by Country
    • 7.2.2 Europe Ulcerative Colitis Market by Disease Type
      • 7.2.2.1 Europe Mild Market by Country
      • 7.2.2.2 Europe Moderate Market by Country
      • 7.2.2.3 Europe Severe Market by Country
    • 7.2.3 Europe Ulcerative Colitis Market by Route of Administration
      • 7.2.3.1 Europe Oral Market by Country
      • 7.2.3.2 Europe Injectables Market by Country
    • 7.2.4 Europe Ulcerative Colitis Market by Country
      • 7.2.4.1 Germany Ulcerative Colitis Market
        • 7.2.4.1.1 Germany Ulcerative Colitis Market by Molecule Type
        • 7.2.4.1.2 Germany Ulcerative Colitis Market by Disease Type
        • 7.2.4.1.3 Germany Ulcerative Colitis Market by Route of Administration
      • 7.2.4.2 UK Ulcerative Colitis Market
        • 7.2.4.2.1 UK Ulcerative Colitis Market by Molecule Type
        • 7.2.4.2.2 UK Ulcerative Colitis Market by Disease Type
        • 7.2.4.2.3 UK Ulcerative Colitis Market by Route of Administration
      • 7.2.4.3 France Ulcerative Colitis Market
        • 7.2.4.3.1 France Ulcerative Colitis Market by Molecule Type
        • 7.2.4.3.2 France Ulcerative Colitis Market by Disease Type
        • 7.2.4.3.3 France Ulcerative Colitis Market by Route of Administration
      • 7.2.4.4 Russia Ulcerative Colitis Market
        • 7.2.4.4.1 Russia Ulcerative Colitis Market by Molecule Type
        • 7.2.4.4.2 Russia Ulcerative Colitis Market by Disease Type
        • 7.2.4.4.3 Russia Ulcerative Colitis Market by Route of Administration
      • 7.2.4.5 Spain Ulcerative Colitis Market
        • 7.2.4.5.1 Spain Ulcerative Colitis Market by Molecule Type
        • 7.2.4.5.2 Spain Ulcerative Colitis Market by Disease Type
        • 7.2.4.5.3 Spain Ulcerative Colitis Market by Route of Administration
      • 7.2.4.6 Italy Ulcerative Colitis Market
        • 7.2.4.6.1 Italy Ulcerative Colitis Market by Molecule Type
        • 7.2.4.6.2 Italy Ulcerative Colitis Market by Disease Type
        • 7.2.4.6.3 Italy Ulcerative Colitis Market by Route of Administration
      • 7.2.4.7 Rest of Europe Ulcerative Colitis Market
        • 7.2.4.7.1 Rest of Europe Ulcerative Colitis Market by Molecule Type
        • 7.2.4.7.2 Rest of Europe Ulcerative Colitis Market by Disease Type
        • 7.2.4.7.3 Rest of Europe Ulcerative Colitis Market by Route of Administration
  • 7.3 Asia Pacific Ulcerative Colitis Market
    • 7.3.1 Asia Pacific Ulcerative Colitis Market by Molecule Type
      • 7.3.1.1 Asia Pacific Small Molecules Market by Country
      • 7.3.1.2 Asia Pacific Biologics Market by Country
    • 7.3.2 Asia Pacific Ulcerative Colitis Market by Disease Type
      • 7.3.2.1 Asia Pacific Mild Market by Country
      • 7.3.2.2 Asia Pacific Moderate Market by Country
      • 7.3.2.3 Asia Pacific Severe Market by Country
    • 7.3.3 Asia Pacific Ulcerative Colitis Market by Route of Administration
      • 7.3.3.1 Asia Pacific Oral Market by Country
      • 7.3.3.2 Asia Pacific Injectables Market by Country
    • 7.3.4 Asia Pacific Ulcerative Colitis Market by Country
      • 7.3.4.1 China Ulcerative Colitis Market
        • 7.3.4.1.1 China Ulcerative Colitis Market by Molecule Type
        • 7.3.4.1.2 China Ulcerative Colitis Market by Disease Type
        • 7.3.4.1.3 China Ulcerative Colitis Market by Route of Administration
      • 7.3.4.2 Japan Ulcerative Colitis Market
        • 7.3.4.2.1 Japan Ulcerative Colitis Market by Molecule Type
        • 7.3.4.2.2 Japan Ulcerative Colitis Market by Disease Type
        • 7.3.4.2.3 Japan Ulcerative Colitis Market by Route of Administration
      • 7.3.4.3 India Ulcerative Colitis Market
        • 7.3.4.3.1 India Ulcerative Colitis Market by Molecule Type
        • 7.3.4.3.2 India Ulcerative Colitis Market by Disease Type
        • 7.3.4.3.3 India Ulcerative Colitis Market by Route of Administration
      • 7.3.4.4 South Korea Ulcerative Colitis Market
        • 7.3.4.4.1 South Korea Ulcerative Colitis Market by Molecule Type
        • 7.3.4.4.2 South Korea Ulcerative Colitis Market by Disease Type
        • 7.3.4.4.3 South Korea Ulcerative Colitis Market by Route of Administration
      • 7.3.4.5 Singapore Ulcerative Colitis Market
        • 7.3.4.5.1 Singapore Ulcerative Colitis Market by Molecule Type
        • 7.3.4.5.2 Singapore Ulcerative Colitis Market by Disease Type
        • 7.3.4.5.3 Singapore Ulcerative Colitis Market by Route of Administration
      • 7.3.4.6 Malaysia Ulcerative Colitis Market
        • 7.3.4.6.1 Malaysia Ulcerative Colitis Market by Molecule Type
        • 7.3.4.6.2 Malaysia Ulcerative Colitis Market by Disease Type
        • 7.3.4.6.3 Malaysia Ulcerative Colitis Market by Route of Administration
      • 7.3.4.7 Rest of Asia Pacific Ulcerative Colitis Market
        • 7.3.4.7.1 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type
        • 7.3.4.7.2 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type
        • 7.3.4.7.3 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration
  • 7.4 LAMEA Ulcerative Colitis Market
    • 7.4.1 LAMEA Ulcerative Colitis Market by Molecule Type
      • 7.4.1.1 LAMEA Small Molecules Market by Country
      • 7.4.1.2 LAMEA Biologics Market by Country
    • 7.4.2 LAMEA Ulcerative Colitis Market by Disease Type
      • 7.4.2.1 LAMEA Mild Market by Country
      • 7.4.2.2 LAMEA Moderate Market by Country
      • 7.4.2.3 LAMEA Severe Market by Country
    • 7.4.3 LAMEA Ulcerative Colitis Market by Route of Administration
      • 7.4.3.1 LAMEA Oral Market by Country
      • 7.4.3.2 LAMEA Injectables Market by Country
    • 7.4.4 LAMEA Ulcerative Colitis Market by Country
      • 7.4.4.1 Brazil Ulcerative Colitis Market
        • 7.4.4.1.1 Brazil Ulcerative Colitis Market by Molecule Type
        • 7.4.4.1.2 Brazil Ulcerative Colitis Market by Disease Type
        • 7.4.4.1.3 Brazil Ulcerative Colitis Market by Route of Administration
      • 7.4.4.2 Argentina Ulcerative Colitis Market
        • 7.4.4.2.1 Argentina Ulcerative Colitis Market by Molecule Type
        • 7.4.4.2.2 Argentina Ulcerative Colitis Market by Disease Type
        • 7.4.4.2.3 Argentina Ulcerative Colitis Market by Route of Administration
      • 7.4.4.3 UAE Ulcerative Colitis Market
        • 7.4.4.3.1 UAE Ulcerative Colitis Market by Molecule Type
        • 7.4.4.3.2 UAE Ulcerative Colitis Market by Disease Type
        • 7.4.4.3.3 UAE Ulcerative Colitis Market by Route of Administration
      • 7.4.4.4 Saudi Arabia Ulcerative Colitis Market
        • 7.4.4.4.1 Saudi Arabia Ulcerative Colitis Market by Molecule Type
        • 7.4.4.4.2 Saudi Arabia Ulcerative Colitis Market by Disease Type
        • 7.4.4.4.3 Saudi Arabia Ulcerative Colitis Market by Route of Administration
      • 7.4.4.5 South Africa Ulcerative Colitis Market
        • 7.4.4.5.1 South Africa Ulcerative Colitis Market by Molecule Type
        • 7.4.4.5.2 South Africa Ulcerative Colitis Market by Disease Type
        • 7.4.4.5.3 South Africa Ulcerative Colitis Market by Route of Administration
      • 7.4.4.6 Nigeria Ulcerative Colitis Market
        • 7.4.4.6.1 Nigeria Ulcerative Colitis Market by Molecule Type
        • 7.4.4.6.2 Nigeria Ulcerative Colitis Market by Disease Type
        • 7.4.4.6.3 Nigeria Ulcerative Colitis Market by Route of Administration
      • 7.4.4.7 Rest of LAMEA Ulcerative Colitis Market
        • 7.4.4.7.1 Rest of LAMEA Ulcerative Colitis Market by Molecule Type
        • 7.4.4.7.2 Rest of LAMEA Ulcerative Colitis Market by Disease Type
        • 7.4.4.7.3 Rest of LAMEA Ulcerative Colitis Market by Route of Administration

Chapter 8. Company Profiles

  • 8.1 Abbott Laboratories
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
  • 8.2 Ajinomoto Co., Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental & Regional Analysis
    • 8.2.4 Research & Development Expenses
  • 8.3 AstraZeneca PLC
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Regional Analysis
    • 8.3.4 Research & Development Expenses
  • 8.4 GlaxoSmithKline PLC
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
  • 8.5 Johnson & Johnson
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental &Regional Analysis
    • 8.5.4 Research & Development Expenses
  • 8.6 Merck & Co., Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Acquisition and Mergers:
  • 8.7 Pfizer, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Regional & Segmental Analysis
    • 8.7.4 Research & Development Expense
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Acquisition and Mergers:
      • 8.7.5.2 Approvals and Trials:
  • 8.8 Sanofi S.A.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expense
  • 8.9 InDex Pharmaceuticals Holding AB
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Recent strategies and developments:
      • 8.9.3.1 Partnerships, Collaborations, and Agreements:
  • 8.10. Eli Lilly And Company
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Segmental and Regional Analysis
    • 8.10.4 Research & Development Expenses

LIST OF TABLES

  • TABLE 1 Global Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 2 Global Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 3 Global Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 4 Global Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 5 Global Small Molecules Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Small Molecules Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Biologics Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Biologics Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 10 Global Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 11 Global Mild Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Mild Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Moderate Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Moderate Market by Region, 2022 - 2028, USD Million
  • TABLE 15 Global Severe Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Severe Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 18 Global Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 19 Global Oral Market by Region, 2018 - 2021, USD Million
  • TABLE 20 Global Oral Market by Region, 2022 - 2028, USD Million
  • TABLE 21 Global Injectables Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Injectables Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Ulcerative Colitis Market by Region, 2018 - 2021, USD Million
  • TABLE 24 Global Ulcerative Colitis Market by Region, 2022 - 2028, USD Million
  • TABLE 25 North America Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 26 North America Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 27 North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 28 North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 29 North America Small Molecules Market by Country, 2018 - 2021, USD Million
  • TABLE 30 North America Small Molecules Market by Country, 2022 - 2028, USD Million
  • TABLE 31 North America Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 32 North America Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 33 North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 34 North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 35 North America Mild Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Mild Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Moderate Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Moderate Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Severe Market by Country, 2018 - 2021, USD Million
  • TABLE 40 North America Severe Market by Country, 2022 - 2028, USD Million
  • TABLE 41 North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 42 North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 43 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America Injectables Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America Injectables Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
  • TABLE 48 North America Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
  • TABLE 49 US Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 50 US Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 51 US Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 52 US Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 53 US Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 54 US Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 55 US Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 56 US Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 57 Canada Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 58 Canada Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 59 Canada Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 60 Canada Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 61 Canada Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 62 Canada Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 63 Canada Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 64 Canada Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 65 Mexico Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 66 Mexico Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 67 Mexico Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 68 Mexico Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 69 Mexico Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 70 Mexico Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 71 Mexico Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 72 Mexico Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 73 Rest of North America Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 74 Rest of North America Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 75 Rest of North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 76 Rest of North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 77 Rest of North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 78 Rest of North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 79 Rest of North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 80 Rest of North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 81 Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 82 Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 83 Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 84 Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 85 Europe Small Molecules Market by Country, 2018 - 2021, USD Million
  • TABLE 86 Europe Small Molecules Market by Country, 2022 - 2028, USD Million
  • TABLE 87 Europe Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 88 Europe Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 89 Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 90 Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 91 Europe Mild Market by Country, 2018 - 2021, USD Million
  • TABLE 92 Europe Mild Market by Country, 2022 - 2028, USD Million
  • TABLE 93 Europe Moderate Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Europe Moderate Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Europe Severe Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Europe Severe Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 98 Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 99 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 100 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 101 Europe Injectables Market by Country, 2018 - 2021, USD Million
  • TABLE 102 Europe Injectables Market by Country, 2022 - 2028, USD Million
  • TABLE 103 Europe Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
  • TABLE 104 Europe Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
  • TABLE 105 Germany Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 106 Germany Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 107 Germany Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 108 Germany Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 109 Germany Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 110 Germany Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 111 Germany Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 112 Germany Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 113 UK Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 114 UK Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 115 UK Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 116 UK Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 117 UK Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 118 UK Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 119 UK Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 120 UK Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 121 France Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 122 France Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 123 France Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 124 France Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 125 France Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 126 France Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 127 France Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 128 France Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 129 Russia Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 130 Russia Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 131 Russia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 132 Russia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 133 Russia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 134 Russia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 135 Russia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 136 Russia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 137 Spain Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 138 Spain Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 139 Spain Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 140 Spain Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 141 Spain Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 142 Spain Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 143 Spain Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 144 Spain Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 145 Italy Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 146 Italy Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 147 Italy Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 148 Italy Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 149 Italy Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 150 Italy Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 151 Italy Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 152 Italy Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 153 Rest of Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 154 Rest of Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 155 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 156 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 157 Rest of Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 158 Rest of Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 159 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 160 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 161 Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 162 Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 163 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 164 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 165 Asia Pacific Small Molecules Market by Country, 2018 - 2021, USD Million
  • TABLE 166 Asia Pacific Small Molecules Market by Country, 2022 - 2028, USD Million
  • TABLE 167 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 168 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 169 Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 170 Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 171 Asia Pacific Mild Market by Country, 2018 - 2021, USD Million
  • TABLE 172 Asia Pacific Mild Market by Country, 2022 - 2028, USD Million
  • TABLE 173 Asia Pacific Moderate Market by Country, 2018 - 2021, USD Million
  • TABLE 174 Asia Pacific Moderate Market by Country, 2022 - 2028, USD Million
  • TABLE 175 Asia Pacific Severe Market by Country, 2018 - 2021, USD Million
  • TABLE 176 Asia Pacific Severe Market by Country, 2022 - 2028, USD Million
  • TABLE 177 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 178 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 179 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 180 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 181 Asia Pacific Injectables Market by Country, 2018 - 2021, USD Million
  • TABLE 182 Asia Pacific Injectables Market by Country, 2022 - 2028, USD Million
  • TABLE 183 Asia Pacific Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
  • TABLE 184 Asia Pacific Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
  • TABLE 185 China Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 186 China Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 187 China Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 188 China Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 189 China Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 190 China Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 191 China Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 192 China Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 193 Japan Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 194 Japan Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 195 Japan Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 196 Japan Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 197 Japan Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 198 Japan Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 199 Japan Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 200 Japan Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 201 India Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 202 India Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 203 India Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 204 India Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 205 India Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 206 India Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 207 India Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 208 India Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 209 South Korea Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 210 South Korea Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 211 South Korea Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 212 South Korea Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 213 South Korea Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 214 South Korea Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 215 South Korea Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 216 South Korea Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 217 Singapore Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 218 Singapore Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 219 Singapore Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 220 Singapore Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 221 Singapore Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 222 Singapore Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 223 Singapore Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 224 Singapore Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 225 Malaysia Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 226 Malaysia Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 227 Malaysia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 228 Malaysia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 229 Malaysia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 230 Malaysia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 231 Malaysia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 232 Malaysia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 233 Rest of Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 234 Rest of Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 235 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 236 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 237 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 238 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 239 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 240 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 241 LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 242 LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 243 LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 244 LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 245 LAMEA Small Molecules Market by Country, 2018 - 2021, USD Million
  • TABLE 246 LAMEA Small Molecules Market by Country, 2022 - 2028, USD Million
  • TABLE 247 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
  • TABLE 248 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
  • TABLE 249 LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 250 LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 251 LAMEA Mild Market by Country, 2018 - 2021, USD Million
  • TABLE 252 LAMEA Mild Market by Country, 2022 - 2028, USD Million
  • TABLE 253 LAMEA Moderate Market by Country, 2018 - 2021, USD Million
  • TABLE 254 LAMEA Moderate Market by Country, 2022 - 2028, USD Million
  • TABLE 255 LAMEA Severe Market by Country, 2018 - 2021, USD Million
  • TABLE 256 LAMEA Severe Market by Country, 2022 - 2028, USD Million
  • TABLE 257 LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 258 LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 259 LAMEA Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 260 LAMEA Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 261 LAMEA Injectables Market by Country, 2018 - 2021, USD Million
  • TABLE 262 LAMEA Injectables Market by Country, 2022 - 2028, USD Million
  • TABLE 263 LAMEA Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
  • TABLE 264 LAMEA Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
  • TABLE 265 Brazil Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 266 Brazil Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 267 Brazil Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 268 Brazil Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 269 Brazil Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 270 Brazil Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 271 Brazil Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 272 Brazil Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 273 Argentina Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 274 Argentina Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 275 Argentina Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 276 Argentina Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 277 Argentina Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 278 Argentina Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 279 Argentina Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 280 Argentina Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 281 UAE Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 282 UAE Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 283 UAE Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 284 UAE Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 285 UAE Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 286 UAE Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 287 UAE Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 288 UAE Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 289 Saudi Arabia Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 290 Saudi Arabia Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 291 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 292 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 293 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 294 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 295 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 296 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 297 South Africa Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 298 South Africa Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 299 South Africa Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 300 South Africa Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 301 South Africa Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 302 South Africa Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 303 South Africa Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 304 South Africa Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 305 Nigeria Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 306 Nigeria Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 307 Nigeria Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 308 Nigeria Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 309 Nigeria Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 310 Nigeria Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 311 Nigeria Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 312 Nigeria Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 313 Rest of LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
  • TABLE 314 Rest of LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
  • TABLE 315 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
  • TABLE 316 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
  • TABLE 317 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
  • TABLE 318 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
  • TABLE 319 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 320 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 321 Key Information - Abbott Laboratories
  • TABLE 322 Key information - Ajinomoto Co., Inc.
  • TABLE 323 KEY INFORMATION - ASTRAZENECA PLC
  • TABLE 324 Key Information - GlaxoSmithKline PLC
  • TABLE 325 Key information - Johnson & Johnson
  • TABLE 326 KEY INFORMATION - MERCK & CO., INC.
  • TABLE 327 Key Information - Pfizer, Inc.
  • TABLE 328 Key Information - Sanofi S.A.
  • TABLE 329 Key Information - InDex Pharmaceuticals Holding AB
  • TABLE 330 Key Information - Eli Lilly And Company

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Ulcerative Colitis Market Share by Molecule Type, 2021
  • FIG 3 Global Ulcerative Colitis Market Share by Molecule Type, 2028
  • FIG 4 Global Ulcerative Colitis Market by Molecule Type, 2018 - 2028, USD Million
  • FIG 5 Global Ulcerative Colitis Market Share by Disease Type, 2021
  • FIG 6 Global Ulcerative Colitis Market Share by Disease Type, 2028
  • FIG 7 Global Ulcerative Colitis Market by Disease Type, 2018 - 2028, USD Million
  • FIG 8 Global Ulcerative Colitis Market Share by Route of Administration, 2021
  • FIG 9 Global Ulcerative Colitis Market Share by Route of Administration, 2028
  • FIG 10 Global Ulcerative Colitis Market by Route of Administration, 2018 - 2028, USD Million
  • FIG 11 Global Ulcerative Colitis Market Share by Region, 2021
  • FIG 12 Global Ulcerative Colitis Market Share by Region, 2028
  • FIG 13 Global Ulcerative Colitis Market by Region, 2018 - 2028, USD Million